The Scientific World Journal / 2013 / Article / Tab 3

Review Article

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials

Table 3

Clinical trials examined assessing the influence of treatment with memantine in moderate-severe AD.

First author and no. in the list of references Severity Mean age yearsMean MMSE at baselineDuration of the study Test

Fox et al. 2012 [17]MMSE ≤ 19Placebo: 84.4 (6.6)
Memantine: 84.9 (6.7)
Placebo: 7.3 (6.4)
Memantine: 7.3 (6.2)
12 weeks149MMSE
SIB
NPI
CMAI
CGI-C

Förstl et al. 2011 [18]MMSE ≤ 27 6 months 4305MMSE
IADL

Herrmann et al. 2011 [19]MMSE 0–15 3 months 24NPI
CGI-C

Schulz et al. 2011 [20]MMSE ≤ 20Memantine:
Placebo:
16.0 (3.7)12 weeks93CERAD-NP
ACDS-ADL-sev
CGI-C

Rainer et al. 2011 [21]MMSE < 20 4 months 350MMSE
CGI

Wilcock et al. 2008 [22]MMSE 14–3Memantine: 76.9 (8.4) 
Placebo: 76.7 (7.9)
Memantine: 9.2 (3.3) 
Placebo: 9.6 (3.1)
6 months 593MMSE
SIB
NPI
ACDS-ADL-sev
CIBIC-plus

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.